Related Experiment Video
Updated: Jul 18, 2025
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Recurrent Multidrug-Resistant Clostridium difficile Infection Secondary to Ulcerative Colitis a Case Report
Arturo P Jaramillo1, Javier Castells2, Sabina Ibrahimli3
1General Practice, California Institute of Behavioral Neurosciences & Psychology, Fairfield, CA 94534, USA.
Insights
Recurrent Clostridioides difficile infection (rCDI) poses a significant challenge, especially in patients with inflammatory bowel disease (IBD). This case highlights the complexity of managing multidrug-resistant CDI (mdCDI) and the need for new treatment guidelines.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Microbiology
Background:
- Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), primarily affects the large bowel.
- Clostridioides difficile infection (CDI) is a common complication, often secondary to UC or antibiotic use.
- Persistent CDI can result from chronic gut dysbiosis and low antibody levels against C. difficile toxins.
Observation:
- This case report details a young woman with multidrug-resistant CDI (mdCDI).
- The patient underwent extensive treatment including antibiotics, anti-inflammatories, corticosteroids, vedolizumab, fecal microbiota transplant (FMT), and immunomodulators.
- Despite multiple therapies, the patient experienced persistent, treatment-resistant CDI.
Findings:
- Multidrug-resistant CDI (mdCDI) presents a complex clinical challenge due to its resistance to various therapeutic agents.
- The management of mdCDI requires prolonged treatment courses, impacting both hospital and outpatient healthcare systems.
- Treatment efficacy is variable, with significant time required to achieve dose-response and time-response.
Implications:
- The case underscores the urgent need for robust clinical trials and meta-analyses to establish definitive therapeutic guidelines for mdCDI.
- Developing standardized treatment protocols is crucial for improving patient outcomes and optimizing healthcare resource allocation.
- Further research into the mechanisms of CDI resistance and host-pathogen interactions is warranted.
Abstract:
IBD consists of two diseases-CD and UC-that affect the digestive tract, with a greater affinity for the large bowel. In this case report, we focus on one of its most common complications. CDI is a pathology that is mostly secondary to UC. Another cause of this bacterial infection is established after the use of antibiotics, most commonly at the hospital level. Around 20 percent of CDI persists because of a chronic dysbiosis of the microbiota and low levels of antibodies against CD toxins. In this case report, we demonstrated mdCDI in a young woman after treatment with multiple drug therapies as well as with semi-invasive procedures as follows: antibiotics (vancomycin, fidaxomicin), anti-inflammatory agents (mesalamine, sulfasalazine), corticosteroids (budesonide, prednisone), integrin receptor antagonists (vedolizumab), several semi-invasive procedures such as fecal transplant microbiota (FMT), aminosalicylates (5-ASA), treatment with tumor necrosis factor (TNF) blockers (adalimumab, golimumab), and immunomodulators (upadcitinib, tofacitinib). This leads us to establish how rCDI and its resistance to different treatments make this a challenge for the health system, both for hospitals and for outpatients, as well as how time-consuming each treatment is from the first intake of the drug until its total efficacy or until patients reach a dose-response and time-response to the disease. Accordingly, this case report and other similar cases reflect the need for randomized control trials or meta-analyses to establish therapeutic guidelines for cases of mdCDI in the near future.
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...